Eli Lilly has successfully challenged Good Life Meds’ claims about the health benefits and personalization of a compounded tirzepatide product.
Lilly, which sells the GLP-1/GIP drug tirzepatide as Mounjaro and Zepbound, challenged the telehealth provider’s claims through BBB National Programs’ National Advertising Division (NAD). The drugmaker, the only provider of FDA-approved tirzepatide products, disputed Good Life’s claims about the effect of the compounded drug on body weight, blood sugar, energy and lean muscle.
After assessing Good Life’s response to the challenge, the NAD recommended that the company stop making the express health benefit and personalization claims challenged by Lilly and modify its ads to remove unsupported implied claims about safety, efficacy and personalization.
Good Life's response to Lilly’s challenge included substantial clinical literature on tirzepatide, information about additive ingredients and real-world evidence, including a Gallup survey and retrospective cohort studies. Yet the NAD found the literature largely concerned Lilly's FDA-approved products. Neither the Gallup survey nor the cohort studies examined Good Life's compounded tirzepatide, the NAD said.
Given those limitations, the NAD ruled that Good Life lacked a reasonable basis for the challenged express health-benefit claims. The NAD recommended that Good Life avoid conveying unsupported claims that its compounded drug is safe and effective for the challenged benefits and offers significant efficacy and weight-loss results.
Good Life voluntarily and permanently discontinued some express and implied claims during the inquiry. The claims related to clinical results, benefits, ingredients, safety and the sourcing of compounded tirzepatide. In its advertiser statement, Good Life said it disagrees with many aspects of the NAD’s decision but will comply with the recommendations.
The case is the latest in a series of challenges that Lilly and Novo have brought against companies providing compounded copies of their GLP-1 drugs. Lilly won a case against Noom in May, and over the past year Novo has successfully challenged claims made by Fletcher Family Medical Center, Regen Doctors and Willow Health Services.